Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

100% human monoclonal antibodies in oncology: hype or breakthrough?

Benay S, Fanciullino R, Mercier C, Iliadis A, Ciccolini J, Lacarelle B.

Curr Top Med Chem. 2012;12(15):1643-8. Review.

PMID:
22978333
2.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
4.

Panitumumab: a review of its use in metastatic colorectal cancer.

Keating GM.

Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. Review.

PMID:
20481659
5.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

6.

Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.

Pohl M, Schmiegel W.

Dig Dis. 2016;34(5):574-9. doi: 10.1159/000445267. Epub 2016 Jun 22.

PMID:
27332557
7.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
8.

Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.

Lo L, Patel D, Townsend AR, Price TJ.

Expert Opin Drug Metab Toxicol. 2015;11(12):1907-24. doi: 10.1517/17425255.2015.1112787. Epub 2015 Nov 16. Review.

PMID:
26572750
9.

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.

Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR.

PLoS One. 2012;7(11):e50925. doi: 10.1371/journal.pone.0050925. Epub 2012 Nov 30.

10.

Integration of panitumumab into the treatment of colorectal cancer.

Gravalos C, Cassinello J, García-Alfonso P, Jimeno A.

Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17. Review.

PMID:
19616446
11.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
12.

[Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].

Piront P, Van Daele D, Belaiche J, Polus M.

Rev Med Liege. 2009 May-Jun;64(5-6):274-8. French.

PMID:
19642458
13.

Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.

J Natl Cancer Inst. 2014 Feb;106(2):djt371. doi: 10.1093/jnci/djt371.

PMID:
24511107
14.

The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.

Bouché O, Beretta GD, Alfonso PG, Geissler M.

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S1-10. doi: 10.1016/S0305-7372(10)00036-8. Review.

PMID:
20189053
15.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
16.

Current controversies in the management of metastatic colorectal cancer.

Vera R, Alonso V, Gállego J, González E, Guillén-Ponce C, Pericay C, Rivera F, Safont MJ, Valladares-Ayerbes M.

Cancer Chemother Pharmacol. 2015 Oct;76(4):659-77. doi: 10.1007/s00280-015-2808-6. Epub 2015 Jun 26. Review.

PMID:
26113053
17.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

18.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.

PMID:
20921465
19.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S.

Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Review.

PMID:
25673558
20.

Panitumumab : leading to better overall survival in metastatic colorectal cancer?

Sebio A, Stintzing S, Stremitzer S, Zhang W, Lenz HJ.

Expert Opin Biol Ther. 2014 Apr;14(4):535-48. doi: 10.1517/14712598.2014.894502. Epub 2014 Mar 5. Review.

PMID:
24593265

Supplemental Content

Support Center